Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.39 - $3.49 $90,103 - $131,573
37,700 Added 121.22%
68,800 $178,000
Q2 2024

Aug 14, 2024

SELL
$2.73 - $4.73 $3,822 - $6,622
-1,400 Reduced 4.31%
31,100 $92,000
Q1 2024

May 15, 2024

SELL
$4.29 - $5.97 $1.2 Million - $1.66 Million
-278,700 Reduced 89.56%
32,500 $147,000
Q4 2023

Feb 14, 2024

SELL
$3.91 - $5.93 $151,317 - $229,491
-38,700 Reduced 11.06%
311,200 $1.78 Million
Q3 2023

Nov 14, 2023

BUY
$4.6 - $7.95 $256,679 - $443,610
55,800 Added 18.97%
349,900 $1.61 Million
Q2 2023

Aug 14, 2023

SELL
$5.66 - $7.59 $94,522 - $126,753
-16,700 Reduced 5.37%
294,100 $1.9 Million
Q1 2023

May 15, 2023

SELL
$7.31 - $11.18 $368,424 - $563,472
-50,400 Reduced 13.95%
310,800 $2.34 Million
Q4 2022

Feb 14, 2023

SELL
$9.48 - $14.52 $368,772 - $564,828
-38,900 Reduced 9.72%
361,200 $3.66 Million
Q3 2022

Nov 14, 2022

BUY
$9.2 - $13.68 $323,840 - $481,536
35,200 Added 9.65%
400,100 $3.96 Million

Others Institutions Holding ABCL

About AbCellera Biologics Inc.


  • Ticker ABCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 285,139,008
  • Market Cap $807M
  • Description
  • AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...
More about ABCL
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.